Can tirzepatide cause headaches?

This site's tirzepatide citation findings do not report headache as a counted trial outcome. The record they hold covers weight (SURMOUNT-1: 2,539 adults, up to 20.9% mean weight loss at 72 weeks on 15 milligrams versus 3.1% on placebo), glycemic head to head (SURPASS-2: 1,879 people over 40 weeks), cardiovascular events (SURPASS-CVOT: 13,299 people; primary MACE 12.2% versus 13.1% on dulaglutide), and sleep apnea (SURMOUNT-OSA at 52 weeks). Headache is not given a percentage here. This FAQ does not invent an adverse-event rate the citations do not contain.

Educational use only. This database summarizes published research and is not medical advice. Where a dose appears it is a record of what a trial or clinic ran, or what people describe doing, with its source attached. Nothing here is a recommendation for personal use.

Part of glp-1 and metabolic peptides. Semaglutide, tirzepatide, retatrutide, and the rest of the incretin and glucagon receptor family.